Company Profiles

driven by the PitchBook Platform

Melinta Therapeutics

Description

Developer of novel small-molecule antibiotics for the treatment of resistant infections. The company discovers, develops and commercializes antibiotic therapies for resistant infections, acute bacterial skin infections, methicillin-resistant staph infections and gonorrhea. Its products include delafloxacin, which is used for complicated skin and soft tissue infections and radezolid, which is used for community acquired pneumonia and uncomplicated skin and soft tissue infections.

2000

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$67M

Latest Deal Amount

$415M

Total Amount Raised

Description

Developer of novel small-molecule antibiotics for the treatment of resistant infections. The company discovers, develops and commercializes antibiotic therapies for resistant infections, acute bacterial skin infections, methicillin-resistant staph infections and gonorrhea. Its products include delafloxacin, which is used for complicated skin and soft tissue infections and radezolid, which is used for community acquired pneumonia and uncomplicated skin and soft tissue infections.

Website:

www.melinta.com

Formerly Known As

Rib-X Designs, Rib-X Pharmaceuticals

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Biotechnology

Primary Office

300 George Street Suite 301 New Haven, CT 06511United States +1 (203) 624-5606
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Melinta Therapeutics's full profile, request a free trial.

Melinta Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Melinta Therapeutics Investors (17)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
ABS VenturesVenture CapitalMinority000 0000000 0000
Axiom Venture PartnersVenture CapitalMinority000 0000000 0000
Cardinal PartnersVenture CapitalMinority000 0000000 0000
Connecticut InnovationsVenture CapitalMinority000 0000000 0000
EuclidSR PartnersVenture CapitalMinority000 0000000 0000
ABS Ventures Venture Capital
Axiom Venture Partners Venture Capital
Cardinal Partners Venture Capital
Connecticut Innovations Venture Capital
EuclidSR Partners Venture Capital

Melinta Therapeutics Executive Team (13)

NameTitleBoard
Seat
Contact
Info
Eugene Sun MDExecutive Vice President, Research & Development & Development & Interim Chief Executive Officer
John TemperatoPresident & Chief Operating Officer
Paul EstremChief Financial Officer
Erin Duffy Ph.DChief Scientific Officer
Rajesh MistryDirector, Investor Relations
Eugene Sun MD Executive Vice President, Research & Development & Development & Interim Chief Executive Officer
John Temperato President & Chief Operating Officer
Paul Estrem Chief Financial Officer
Erin Duffy Ph.D Chief Scientific Officer
Rajesh Mistry Director, Investor Relations

Melinta Therapeutics Board Members (9)

NameRepresentingRoleSinceContact
Info
Cecilia GonzaloMelinta TherapeuticsBoard Member000 0000
Christopher KiritsySelfBoard Member000 0000
Erik AkhundSelfBoard Member000 0000
John SununuSelfBoard Member000 0000
Kevin FerroVatera Healthcare PartnersChief Executive Officer000 0000
Cecilia Gonzalo Board Member Melinta Therapeutics
Christopher Kiritsy Board Member Self
Erik Akhund Board Member Self
John Sununu Board Member Self
Kevin Ferro Chief Executive Officer Vatera Healthcare Partners
Request full access to PitchBook